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Abstract: 
Background:Choledocholithiasis constitutes the main aetiology of non-malignant 
biliary obstructions. The prevalence of CBD stones in patients with symptomatic 
gallstones varies but probably lies between 8 % and 20%. Failure to detect CBD 
stones leads to potentially life-threatening complications such as cholangitis, 
pancreatitis or obstructive jaundice. ERCP, MRCP and Intraoperative 
cholangiography have high sensitivity in detecting CBDS but its routine use is 
associated with increased complications, costs and operating room time. In this 
study we felt a need for useful predictive factors to predict patients having 
choledocholithiasis so that these modern interventions can be selectively utilized, 
and to determine the patients who need CBD exploration during cholecystectomy. 
Patient and Methods :Data was collected from consecutive patients diagnosed 
with cholelithiasis and choledocholithiasis by clinical presentations, 
ultrasonography and liver function tests at Ibn Sena Hospital, then CBD stone 
confirmed by  definitive testing for choledocholithiasis ( ERCP, MRCP or 
common bile duct [CBD] exploration). These clinical, biochemical and 
radiological findings were considered as predictive factors and analysed 
retrospectively.  
Results:A total of 72 patiens satisfied our inclusion criteria. Of those, 86% (n=62) 
had CBD stone, and 14% (n=10) did not have CBD stone. Several variables were 
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analysed and showed that total bilirubin, ALP, AST, ALT, dilated CBD>6mm and 
visible CBD stone on ultrasonography were significantly associated with 
choledocholithiasis (p<0.05). Then four predictive factors (total bilirubin, ALP, 
dilated CBD > 6mm and visible CBDS on ultrasonography )  were used to build a 
simple scoring system. 
Conclusion:our results showed that abnormal liver function tests, multiple 
gallbladder stones, dilated CBD more than 6mm and visible CBD stone in 
ultrasonographic were statistically significant for detection of choledocholithiasis. 
Also we suggest a simple scoring system as a predictor for CBD stones. 
 
Introduction: 
Choledocholithiasis or common bile duct stones (CBDS) constitute the main 
aetiology of non-malignant biliary obstructions. The quoted prevalence of CBD 
stones in patients with symptomatic gallstones varies but probably lies between 8 
% and 20% 
(1)
. The ratio of women to men with CBD stone is 0.89:1,  although 
the prevalence of gallbladder stone is higher in women than in men (1.22:1) 
(2)
. 
The incidence of gallstones increases with increasing parity, and biliary sludge is 
formed in approximately 30% of pregnant women; 1-3% of these pregnant 
women with biliary sludge form gallstones 
(3,4)
.  Similarly ,gallbladder disease is 
found in 5-8% of young women but in 25-30% of women over 50 years of age 
(5)
. 
Thus, risk factors for gallstones include biological factors such as increasing age, 
female gender and pregnancy.
(6) 
Common bile duct stones are associated with a significant number of hospital 
admissions, readmissions, and potentially life- threatening  complications such as 
Cholangitis, acute pancreatitis, obstructive jaundice, and even fatal complications. 
The obstructive jaundice secondary to the presence of  lithiasis in the CBD are the 
most common clinical presentations of CBDS 
(7)
. Therefore, clinicians should aim 
to maximize the recognition of choledocholithiasis while minimizing unnecessary 
endoscopic retrograde cholangiopancreatography (ERCP), which carries up to a 
15 % risk of post ERCP pancreatitis, as well as the risks of postsphincterotomy 
hemorrhage, cholangitis, perforation, and anesthesia-induced adverse events 
(8, 9)
. 
Diagnosis of choledocholithiasis is not always straight forward  and clinical 
evaluation and biochemical tests are often not sufficiently accurate to establish a 
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firm diagnosis. Common bile duct stones may be discovered preoperatively, 
intraoperatively or postoperatively. The standard preoperative workup for patients 
presenting with symptoms attributable to cholelithiasis includes liver function 
tests, and abdominal ultrasound. These tests, combined with clinical examination 
and history, constitute the entire workup for most patients. Abnormalities in these 
tests may suggest the presence of choledocholithiasis, abdominal ultrasound and 
liver function tests (LFT) are used routinely to predict CBD stones. Elevated 
serum bilirubin and alkaline phosphatase typically reflect biliary obstruction but 
these are neither highly sensitive nor specific for CBD stones. Excepting obvious 
jaundice, a raised GGT level has been suggested to be the most sensitive and 
specific indicator of CBD stones. A value of greater than 90 U/L has been 
proposed to indicate a high risk of choledocholithiasis. However, laboratory data 
may be normal in as many as a third of patients with choledocholithiasis, 




In order to help select from the various diagnostic and therapeutic options, 
patients may be classified preoperatively into high, moderate or low risk groups. 
The high risk (> 50% risk) group includes those patients with obvious clinical 
jaundice or cholangitis, choledocholithiasis or a dilated CBD on ultrasonography. 
Patients with a history of pancreatitis or jaundice, elevated preoperative bilirubin 
and alkaline phosphatase levels or multiple small gallstones carry a moderate 
(10%-50%) risk of choledocholithiasis. Patients with large gallstones, without a 
history of jaundice or pancreatitis and with normal liver function tests are 
considered unlikely to have CBD stones and therefore at low risk (<5%)
(11-13)
. 
Today, laparoscopic cholecystectomy (LC) is considered as the gold standard for 
treatment of cholelithiasis. However, a surgeon needs to rule out the presence of 
choledocholithiasis and treat the problem if present. Historically, exploration of 
the CBD was recommended in patients with a history of jaundice or pancreatitis, 
operative findings of multiple gallbladder stones, single-faceted stone, dilated 
CBD and palpable stone in the bile duct. Observance of these criteria for CBD 
exploration  led to a significant proportion of unnecessary CBD explorations, and 
a patient suffered complications like prolong T-tube drainage and biliary stricture 
(14)
. To avoid these complications, intraoperative cholangiography (IOC) was 
introduced which meant the availability of a portable X-ray machine and 
increased operative time of 30 ±10 min 
(15)
. Now endoscopic retrograde 
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cholangiopancreaticography (ERCP) gradually replaced  IOC as a preferred 
investigation for detection of choledocholithiasis 
(16)
. The major advantage was its  
therapeutic role in clearing the CBD off stone and achieving drainage by stent 
insertion. However, when used as a diagnostic investigation  alone, the risks of 
complications like pancreatitis, cholangitis and iatrogenic injuries were 
unacceptable.The development of magnetic resonance 
cholangiopancreaticography (MRCP) and endoscopic ultrasonography (EUS) 
have provided a safe alternative for detecting CBD stones. The use of endoscopic 
retrograde cholangiopancreatography (ERCP) as a diagnostic tool should be 
minimised as it carries considerable risk (5–10%) of post-procedural 
complications: acute pancreatitis (1.3–6.7%), bleeding (0.7–2%), acute cholangitis 
(0.5–5%), duodenal perforation (0.3–1%) 
('17,18)
. Recently, the American Society 
for Gastrointestinal Endoscopy (ASGE) published a guideline for patients who are 
planned to undergo ERCP for suspected CBDS. According to this guideline, in 
patients with symptomatic gallbladder stone, very strong (CBDS on 
transabdominal ultrasonography (US), clinical ascending cholangitis or total 
bilirubin > 4 mg/dL), strong (dilated CBD > 6 mm on US with gallbladder in situ 
and total bilirubin level of 1.8–4.0 mg/dL) and moderate (abnormal liver 
biochemical test other than bilirubin, age more than 55 years and clinical findings 
of biliary pancreatitis) predictive factors have been proposed. Patients who have 
any of very strong or two of the strong predictors are defined to have a high risk 
for CBDS and preoperative ERCP has been recommended in these patients. 
Patients without any predictive factor are defined to have low risk and in these 
patients laparoscopic cholecystectomy is recommended without further 
investigation. The remaining patients are defined to have intermediate risk and in 
these patients confirmation of the stone is recommended according to the clinical 
preference, either preoperative (endoscopic ultrasound (EUS) or magnetic 
resonance cholangiopancreatography (MRCP)) or intraoperative (laparoscopic 
intraoperative cholangiography (IOC)). It is noticed that adverse events occur 
more often in patients with low risk of choledocholithiasis 
(18)
. Therefore the best 
possible patient selection for ERCP procedure is needed.  However, because the 
unnecessary CBD exploration, and  the cost, the limited availability of these 
investigations and it is complication, in this study  we felt a need for useful 
predictive factors to predict a patients having a high risk of choledocholithiasis so 
that these modern  interventions can be selectively utilized 
(19)
. 
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Patient and Methods: 
Data was collected from consecutive patients diagnosed with cholelithiasis and 
choledocholithiasis by clinical presentations, ultrasonography and liver function 
tests at Ibn Sena Hospital which were satisfying our inclusion criteria ( Age > 18 
years, patient with cholelithiasis and choledocholithiasis, or symptoms that could 
suggest suspected choledocholithiasis, procedural indications of pancreatitis, 
ascending cholangitis, biliary dilatation, and abnormal liver function test results). 
Then clinical presentations ( biliary colic, jaundice, itching, dark urine, pale stool, 
acute pancreatitis and ascending cholangitis ), LFT ( Total bilirubin, ALP, AST 
and ALT ) and ultrasonographic findings ( dilated CBD > 6mm, visible CBD 
stone and number of gallbladder stone ) were analyzed retrospectively by using 
SPSS computer program version 25. Chi square, Student t test and descriptive 




A total of 72 patients in Ibn Sina specialized hospital diagnosed as cholelithiasis 
and choledocholithiasis by ultrasonography and liver function tests, then 
confirmed by either MRCP or ERCP, all of them satisfied the inclusion criteria. 
Of all patients, 86% (n=62) confirmed to have CBD stone, and 14% (n=10) did 
not have CBD stone. 
The age range was from 26 to 90 years   [mean age of 52.26 ±13.9]. Male were 
26% (n=19) and female were 73% (n=53), and male to female ratio was 1:3 
(Figure 1.3).  
We studied different presentations of CBD stone as predictive factors.  Of those 
72 patients, there was 63% (n=46) who presented with biliary colic, 84.8% (n=39) 
of them with CBD stone and 15.2% (n=7) without CBD stone. 33% (n=24) of 
total patients presented with itching, 87.5% (n=21) of them with CBD stone and 
12.5% (n=3) without CBD stone.  66% (n=48) presented with jaundice, 89.6% 
(n=43) of them with CBD stone and 10.4% (n= 5) without CBD stone. A 76% 
(n=55) presented with dark urine, 92.7% (n=51) of them with CBD stone and 
7.3% (n=4) without CBD stone, it had statistically significant (p <0.05).  36% 
(n=26) presented with pale stool, 88.5% (n=23) of them with CBD stone and 
11.5% (n=3) without CBD stone. There was only 5% (n=4) patients who 
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presented with pancreatitis, and all of them had CBD stone. Also there was only 
4% (n=3) patients who presented with cholangitis, and all of them had CBD stone 
(Table 1.3). 
There were 70% (n=51) patients who had total bilirubin level more than 2mg/dl, 
92.2% (n=47) of them with CBD stone and 7.8% (n=4) without CBD stone.  30% 
(n=21) had total bilirubin level less than 2mg/dl, 71.4% (n=15) of them with CBD 
stone and 28.6% (n=6) without CBD stone, it had statistically significant 
(p<0.05). The mean of total bilirubin was 4.9 ± 5.77 (Table 2.3, Figure 2.3). 
There were 61.1% (n=44) patients who had ALP level more than 150 IU/L, 95.5% 
(n=42) of them had CBD stone and 4.5% (n=2) without CBD stone.  39.9% 
(n=28) had ALP level less than 150 IU/L, 71.4% (n=20) of them with CBD stone 
and 28.6% (n=8) without CBD stone, it had statistically significant (p<0.05). The 
mean of ALP level was 282.6 ± 179.22 (Table 2.3, Figure 3.3). 
A 52.8% (n=38) patients had AST level more than 40 IU/L; all of them had CBD 
stone. And 47.2% (n=34) had AST level less than 40 IU/L, 70.6% (n=24) of them 
had CBD stone and 29.4% (n=10) without CBD stone, it had statistically 
significant (p<0.05). The mean of AST was 54.08 ± 51.805 (Table 2.3, Figure 
4.3). 
The ALT level was more than 40 IU/L in 43.1% (n=31) patients, 96.8% (n=30) of 
them with CBD stone and 3.2% (n=1) without CBD stone. And it was less than 40 
IU/L in 56.9% (n=41), 78% (n=32) of them with CBD stone and 22% (n=9) 
without CBD stone, it had statistically significant (p<0.05). The mean of ALT was 
51.89 ± 74.83 (Table 2.3, Figure 5.3). 
There were 73.6% (n=53) had a visible common bile duct stone on 
ultrasonography, 94.3% (n=50) of them with CBD stone and 5.7% (n=3) without 
CBD stone. 26.4% (n=19) had no visible CBD stone on ultrasonography, 63.2% 
(n=12) of them with CBD stone and 36.8% (n=7) without CBD stone, it had 
statistically significant (p<0.05) [figure (6)]. Of 72 patients 88.9% (n=64) had 
dilated common bile duct more than 6 mm, 92.2% (n=59) of them had CBD stone 
and 7.8% (n=5) without CBD stone. 11.1% (n=8) had a normal CBD diameter, 
37.5% (n=3) of them had CBD stone and 62.5% (n=5) without CBD stone, it had 
statistically significant (p<0.05) (Table 3.3). 
There were 58.3% (n=48) had multiple gall stones on ultrasonography, 89.6% 
(n=43) of them with CBD stone and 10.4% (n=5) without CBD stone. 19.4% 
(n=14) had solitary gall stone, 85.7% (n=12) of them with CBD stone and 14.3% 
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(n=2) without CBD stone.  13.9% (n=10) had sludge on ultrasonography, 70% 
(n=7) of them had CBD stone and 30% (n=3) without CBD stone. The number of 
gall stones was statistically significant (p<0.05) (Table 3.3). 
These statistically significant predictive factors were used to develop scoring 
system. Total bilirubin, ALP, dilated CBD and visible CBD stone on 
ultrasonography were included in scoring system. Analysis of each predictive 
factor showed 92.9% positive predictive value (PPV) for total bilirubin, 95.5% 
PPV for ALP, 92.2% PPV for CBD diameter > 6 mm and 94.3% PPV for visible 
CBD stone on ultrasonography. Each of these factors was given a score of 1. The 
scoring system was applied to all total patients. The scoring system was studied 
by assessing the positive and negative predictive values for diagnosing 
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Table (1.3): Clinical presentations 
 
Figure (2.3): histogram of total bilirubin (n=72) 
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Figure (3.3): histogram of alkaline phosphatase 
 
Figure (4.3): histogram of aspartate aminotransferase 
 
Gezira Journal of Health Sciences June 2020 Volume 16(1)________________ 




Figure (5.3): histogram of alanine aminotransferase 
 
 
Table  (2.3): Association of liver function tests with choledocholithiasis(n=72) 
 
 Presence of CBD stones Total from 72 P value 
Yes No 
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Table  (3.3): Association of Ultrasonographic findings with 
choledocholithiasis 



















































Table (4.3): Performance characteristics of scoring system 





PPV for CBD 
stone(%) 
 




0 2 0% 100% 
1 
 
2 4 33.3% 66.7% 
2 
 
14 2 87.5% 12.5% 
3 
 
18 2 90% 10% 
4 28 2 100% 0% 
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Due to limited availability of ERCP, EUS, Intraoperative cholangiogram and 
MRCP in Sudan along with their complications and cost, we attempted to achieve 
a more reasonable and safer approach for patients suspected to suffer from CBD 
stone. Then we studied the performance of different predictive factors for CBD 
stone in our population including the presentations, liver function test and 
ultrasonographic findings. Then we suggested a simple scoring system for 
predicting a possible diagnosis of choledocholithiasis in patients with 
cholelithiasis especially those planed for cholecystectomy. 
In our study the mean age was 52.26 ±13.9 and male to female ratio was 1:3. A 
study conducted by Bilal O. Aljiffry et al in Saudi Arabia showed that the age had 
statistically significance for prediction of CBD stone and they included it in their 
scoring system for detection of CBD stone 
(20)
. Barkun An el at showed that age 
plays a significant role in predicting CBD stone, and the prevalence of gallstone 
increases with age 
(12)
. Our results similar to study of Anas Kadah el at, they 
divided their total patients into two groups according to presence of CBD stone, 
the mean age of groups A and B were 52.6 ± 19.5 and 63.1 ± 19.6 years, 
respectively and it is statistically significance 
(21)
. On contrast, Ausra Aleknaite et 
al, showed that the mean age of their total patients was 65.2 ± 17.9, mean age of 
patients with CBD stone was 66.3 ± 17.7 and mean age of patients without CBD 
stone was 63.3 ± 18.1, and they reveal that patient's age and sex distribution did 
not show differ statistical significance 
(22)
. Also in study conducted by Michele 
Grande et al, revealed that mean age was 52 ± 15.3 years which is similar to our 
study [23]. Frederic Part et al, showed that The prevalence of  CBD  stone  was  
shown  to  increase  from  14%  in  patients  less  than 70  years  old,  to  32%  in  
patients  over  70  years  old  in  a  group  of patients  referred  for  EUS  to  rule  
out  CBD  stone 
(24)
. 
Bivariate analyses of the presentations for choledocholithiasis in our study 
(jaundice, biliary colic, itching, dark urine, pale stool, pancreatitis and cholangitis) 
were not statistically significant (p < 0.05), acute pancreatitis and cholangitis had 
100% PPV in our study but they were not statistically significant because there 
was small study sample. Ausra Aleknaite et al showed that jaundice, acute biliary 
pancreatitis and cholangitis were statistically significant 
(22)
. Megan A. Adams et 
al, found that biliary pancreatitis had a sensitivity of 41.7% and specificity of 
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68.9% in diagnosing choledocholithiasis, with over all accuracy of 58.9% 
(25)
. 
Huiqin He et al showed that acute pancreatitis decreased the likelihood for 
choledocholithiasis in definitive test 
(26)
. In study conducted by Saurabh Sethi et 
al, Univariate logistic regression analysis was carried out to test the association 
between the eight variables used for ASGE stratification and the presence of stone 
at ERCP. Suspected ascending cholangitis (OR=1.9), bilirubin values between 1.8 
mg/dl and 4 mg/dl (OR=1.7), elevation in liver enzymes (OR=2.1), and 
choledocholithiasis seen on pre-ERCP imaging (OR=3.6) were found to be 
significant predictors for the presence of stones at ERCP 
(27)
. In study Rodrigo M. 
Narvaez-Rivera et al, multivariable logistic regression analysis showed that the 
presence of ascending cholangitis and the absence of biliary pancreatitis (OR 
3.23; 95% CI, 1.81-5.77; p < 0.001) were independently associated with the 
presence of a stone on ERCP. The occurrence of biliary pancreatitis was a strong 
protective factor for the presence of a retained CBD stone (OR 0.30; 95% CI, 
0.17-0.55; p < 0.001) 
(28)
.  
In our study the total bilirubin, alkaline phosphates (ALP), aspartame 
aminotransferase (AST) and alanine aminotransferase (ALT) were significantly 
associated with choledocholithiasis (p< 0.05). In study conducted by Bilal O. 
Aljiffry et al, showed that the ALP, ALT and total bilirubin were significantly 
correlated with the CBD stone 
(20)
. Our study was similar to study conducted by 
Sheshang U. Kamath et al, which showed that on bivariate analysis, total bilirubin 
>2 mg/dl, amylase >90 IU/L, ALP > 190 IU/L, and AST and ALT > 40 IU/L were 
significantly associated with choledocholithiasis (p < 0.05) 
(19)
. Large prospective 
study by Videhult et al, analyzed these biochemical parameters in cohort of 
patients with symptomatic cholelithiasis which found ALP and total bilirubin to 
predict choledocholithiasis 
(29)
. In study conducted by Ming-Hsun Yang et al, 
found that gamma glutamyle transferase (GGT), ALP, total bilirubin, ALT and 
AST were significantly associated with choledocholithiasis. And after 
multivariate analysis of five biochemical predictors, the GGT appeared to be the 
most powerful independent predictor, with an odds ratio of 3.20. ALP and total 
bilirubin were also independent predictors 
(30)
. W. K. Peng et al studied the role of 
LFT in evaluating CBD stone in patients with cholelithiasis. Using several cut-off 
levels, γ-glutamyl transpeptidase (GGT) had the highest specificity, positive 
predictive value and negative predictive value, comparable to a scoring system 
that combined all LFTs. Bilirubin was the least specific and predictive. Also 
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represented a one in three chance of CBD stones when the GGT level was above 
90 units/l and a one in 30 chance when the level was less than 90 units/l 
(31)
. 
Alejandro L. Suarez et al, found that in multivariable logistic regression analysis 
revealed that a bilirubin level higher than 4 mg/dl [odds ratio 4.85; 95 % 
confidence interval (CI) 1.82–12.92] and a stone visualized on US (odds ratio 6.4; 
95 % CI 1.50–27.3) were independently associated with the presence of a stone on 
ERCP, EUS, MRCP, or IOC 
(32)
. Mohammad Zare et al, found that mean of AST. 
ALT, ALP and total and direct bilirubin had no significant differences between 
two study groups. In logistic regression analysis, after entering into the model 
only CBD diameter (OR: 20; P=0.00) and elevated serum level of ALT (OR: 2; 
P=0.04) were remained into the model and were known as independent predictor 
of cholelithiasis. Elevated level of liver enzymes had not main role in CBD 
diagnosis and ERCP had no to perform for suspicious CBD stone only with 
elevated liver enzyme and even with normal ultrasonography findings 
(33)
. 
The results of our study showed that dilated CBD more than 6 mm, visible CBD 
stone and number of gallstones on ultrasonography were statistically significant 
for choledocholithiasis. In study conducted by Bilal O. Aljiffry et al, showed that 
the presence of a CDB acoustic shadow during ultrasonography and CBD 
diameter of > 10mm were significantly correlated with choledocholithiasis 
(20)
.  
Evaluation of different criteria in study conducted by Ausra Aleknaite et al 
showed that dilated CBD and presence of CBD stone on ultrasonography were 
stronger predictors than elevated total bilirubin 
(22)
. Megan A. Adams et al 
revealed that the presence of a stone on ultrasonography had sensitivity of 21.8%, 
specificity of 93.5 and an accuracy of 63.4% in diagnosing choledocholithiasis 
(25)
. CBD width by ultrasonography in study conducted by Anas Kadah et al, were 
statistically significant in univariate and multivariate analysis 
(21)
. Michele 
Grande, MD et al, showed that number of gallbladder stones and CBD diameter 
(mm) were statistically significant 
(23)
. In retrospective study conducted by Ufuk 
B. Kuzu et al, according to the American Society for Gastrointestinal Endoscopy 
(ASGE) found that all very strong and strong predictors were found to be 
significantly higher among patients who had CBD stone, detection of CBD stone 
by ultrasonography and dilated CBD were observed to be independent risk factors 
associated with the existence of CBD stone 
(34)
. Maffalda Sousa et al, included 
patients in their study with gallbladder in situ and with cholecystectomy. They 
showed that the ASGE criteria true positive rate was similar between patients with 
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and without cholecystectomy. The prevalence of choledocholithiasis on ERCP 
was 71% in cholecystectomized and 70% in non-cholecystectomized. In addition, 
both the presence and the diameter of the CBD stone were predictors of positive 
ERCP in both groups. In contrast, the diameter of the CBD was predictor of 
positive ERCP only in non-cholecystectomized patients 
(35)
. Multivariate logistic 
regression analysis in study conducted by Saurabh Sethi et al was done to test the 
association between eight predictor variables used for ASGE stratification and the 
presence of stone at ERCP. Only the presence of choledocholithiasis on imaging 
studies (OR: 3.98; 95% CI2.3–6.8; P<0.01), and bilirubin values between 
1.8mg/dl and 4mg/dl (OR: 1.9; 95% CI 1.0–3.4; P=0.04) were found to be 
independent predictors of stones at ERCP 
(27)
. In study Rodrigo M. Narvaez-
Rivera et al, multivariable logistic regression analysis showed that a CBD > 6 mm 
(OR 2.21; 95% CI, 1.20-4.10; p = 0.011) and CBD stone visualized on 
transabdominal US (OR 3.33; 95% CI, 1.48-7.52; p = 0.004) were independently 
associated with the presence of a stone on ERCP 
(28)
. 
In our study we used most significant predictive factors to develop a simple 
scoring system. Total bilirubin, ALP, dilated CBD and visible CBD stone on 
ultrasonography were included in the score. In study conducted by Bilal O. 
Aljiffry et al, the scoring system were developed from predictive factors such as 
the presence of CBD acoustic shadow during ultrasonography, a CBD diameter of 
> 10 (mm), ALP > 200 IU, ALT > 220 IU, elevated serum bilirubin level and a 
male age of > 50 years 
(20)
. Sheshang U. Kamath et al, build a scoring system 
consisting of four factors: dilated bile duct on ultrasonography > 6 mm, total 
bilirubin > 2mg/dl, ALP > 190 IU/L, AST > 40 IU/L. Each of these predictors 
was given a score of 1 
(19)
. N. Menezes et al showed that multivariate analysis of 
age, sex, jaundice, ascending cholangitis, transaminases, CBD diameter and CBD 
stone in ultrasonography were statistically significant and used for a predictive 
scoring system for choledocholithiasis. The overall sensitivity and specificity of 
this score were 82% and 80%, respectively 
(36)
. Jingjing L. Sherman et al, 
developed a score consist of CBD diameter, GGT, ALP, and total bilirubin A 
score of 0 had negative predictive value (NPV) of 100% for CBD stones (P 
<.001). Scores of 1 and 2 had NPV of 81% and 83%, respectively. A score of 3 
had NPV of 60%. A score of 4 had PPV of 67% (P = .002). A score of 5 had PPV 
of 100% (P <.001). The overall accuracy of the scoring system was 88% 
(37)
. 
This study has several limitations. First, GGT which has been considered by 
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previous studies as an important predictor of choledocholithiasis was not assessed 
in our study. Second limitation that we did not validate our findings in an 
independent validation cohort. Third, we observed a delay in the time between the 
patient's diagnosis and the time of ERCP, and these delays may theoretically 
increase the possibility that CBD stones were passed before ERCP, and thereby 
increase the number of negative ERCP results. The last limitation is the small 
sample size and lack of proper diagnostic techniques. 
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